Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q4 EPS of ($0.54), $0.29 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Stifel on Eos Energy Enterprises (EOSE) amid 10% gain: 'we view the collaboration with Google as a positive step for EOSE'
• Yatsen Holding (YSG) Reports Q2 Loss of $0.16
• DA Davidson Reiterates Buy Rating on CrowdStrike (CRWD) Ahead of User Conference